MIRANDA ENGELDINGER: Open Payments
NPI 1699456087 · AMES, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$940 in 74 payments from 13 companies in 2025. Trend: 2023 $408 · 2024 $1,076 · 2025 $940
Food & beverage: $940
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 29 | $331 |
| ABBVIE INC. | 22 | $210 |
| Teva Pharmaceuticals USA, Inc. | 3 | $60 |
| Neurocrine BioSciences, Inc. | 3 | $58 |
| Corium, LLC | 4 | $57 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $47 |
| Alkermes, Inc. | 2 | $40 |
| Janssen Pharmaceuticals, Inc | 2 | $35 |
| MDD US Operations, LLC | 2 | $29 |
| Neos Therapeutics, LP | 2 | $29 |
Products named: VRAYLAR, REXULTI, ABILIFY ASIMTUFII, INGREZZA, ABILIFY MAINTENA, Azstarys, CAPLYTA, ARISTADA.
Industry payments across IA — which companies pay providers there.
